AbbVievsRapid Micro Biosystems

ABBV and RPID stock compared: price, dividend, valuation and results, from SEC filings.

RPID

Rapid Micro Biosystems, Inc.

$0.65

Value $29M

-2.98%
RPID's page

AbbVie (ABBV) has a market value of $522B and Rapid Micro Biosystems (RPID) $29M. Over the last year, with dividends, ABBV moved +30.3% and RPID -84.3%. Dividend yield: ABBV 2.35%, RPID none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    RPID$29M

    ABBV is 17,935 times RPID

  • Revenue, 12 months

    ABBV$66.0B

    RPID$35M

    ABBV is 1,877 times RPID

  • Net income, 12 months

    ABBV$10.3B

    RPID-$51M

  • Operating margin

    ABBV32.2%

    RPID-141.5%

    173.6 points apart

  • ROIC

    ABBV25.7%

    RPID-79.9%

    105.5 points apart

  • P/E

    ABBV50.7

    RPID–

  • Dividend yield

    ABBV2.4%

    RPID0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    RPID-96.2%

    297.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.6%

RPID-96.2%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsRPIDWith dividends
1 year since November 12, 2025+30.3%Price +26.5%-84.3%Price -84.3%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%-34.9%-13.3% a yearPrice -34.9%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%-96.2%-48.1% a yearPrice -96.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieRPIDRapid Micro Biosystems

Valuation

ABBVRPID
Valuation
Price$295.03$0.65
Market value$522B$29M
Enterprise value (EV)$592B–
P/E50.7–
P/E, 5-year median57.0–
P/B–1.6
EV/EBIT27.9–
Free cash flow yield3.6%–

Results and growth

ABBVRPID
Results and growth
Revenue, 12 months$66.0B$35M
Net income, 12 months$10.3B-$51M
Free cash flow, 12 months$18.9B-$40M
Earnings per share, 12 months$5.81-$1.11
Revenue growth, year on year8.6%19.7%
Revenue growth a year, past+5.9%over 5 years+15.9%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVRPID
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%-141.5%
Net margin15.7%-145.6%
ROIC25.7%-79.9%
ROE–-150.4%

Balance sheet

ABBVRPID
Balance sheet
Cash$10.8B$20M
Total debt$80.9B–
Net debt / EBITDA3.2–
Interest cover7.1×-21.2×

Dividends and buybacks

ABBVRPID
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or RPID

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Rapid Micro Biosystems?

By market value, AbbVie ($522B) is about 17,935.0 times Rapid Micro Biosystems ($29M), at today's prices.

How did ABBV and RPID stock do over the last 5 years?

Since November 12, 2021, ABBV's price moved +152.2% and RPID's -96.2%. With dividends: ABBV +201.5% (+24.7% a year), RPID -96.2% (-48.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or RPID?

The dividend yield at today's price is 2.35% for AbbVie and none for Rapid Micro Biosystems. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Rapid Micro Biosystems?

Over the last twelve months, the net margin was 15.7% for AbbVie and -145.6% for Rapid Micro Biosystems, and the operating margin 32.2% and -141.5%. Revenue was $66.0B and $35M.

Which is the better investment, AbbVie or Rapid Micro Biosystems?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.